Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth announces phase II study data

Wyeth announces phase II study data

15th December 2008

Wyeth’s Pharmaceuticals division has announced data from a phase II study of neratinib (HKI-272).

Data from tests on women with advanced HER-2-positive breast cancer, data suggested the therapy has antitumour activity.

The drug is an investigational orally-administered potent and irreversible dual inhibitor of the HER-2 and EGFR kinases.

Harold Burnsteirn, lead study investigator at Dana-Farber Cancer Institute, said: “Neratinib demonstrated activity against trastuzumab-resistant and trastuzumab-naive HER-2-positive breast cancer.

“These results warrant ongoing study to see whether neratinib will fit into our armamentarium of anti-HER2 drugs.”

Involving 136 women, the phase II study evaluated the safety and efficacy of a daily 240 mg oral dose of the drug, with the primary end point being the 16-week progression-free survival rate.

Gary Stiles, chief medical officer at Wyeth, added the data provides “important insight” into “potential clinical utility” of neratinib in HER2-positive breast cancer.

Last week, the company submitted a European Marketing Authorisation Application for its 13-valent pneumococcal conjugate vaccine.

The jab – for children aged between two months and five years old – includes the 13 most prevalent pneumococcal serotypes associated with pneumococcal disease.

Founded in 1926, Wyeth is headquartered in Madison, US and operates in more than 100 countries.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.